382 related articles for article (PubMed ID: 22278425)
1. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
[No Abstract] [Full Text] [Related]
3. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
[TBL] [Abstract][Full Text] [Related]
4. Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
van der Pas R; van Esch JH; de Bruin C; Danser AH; Pereira AM; Zelissen PM; Netea-Maier R; Sprij-Mooij DM; van den Berg-Garrelds IM; van Schaik RH; Lamberts SW; van den Meiracker AH; Hofland LJ; Feelders RA
Eur J Endocrinol; 2014 Feb; 170(2):181-91. PubMed ID: 24165019
[TBL] [Abstract][Full Text] [Related]
5. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
6. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
8. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?
Barbot M; Albiger N; Ceccato F; Zilio M; Frigo AC; Denaro L; Mantero F; Scaroni C
Pituitary; 2014 Apr; 17(2):109-17. PubMed ID: 23468128
[TBL] [Abstract][Full Text] [Related]
10. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease.
van den Bosch OF; Stades AM; Zelissen PM
Clin Endocrinol (Oxf); 2014 Feb; 80(2):184-90. PubMed ID: 23841642
[TBL] [Abstract][Full Text] [Related]
11. Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.
Barbot M; Guarnotta V; Zilio M; Ceccato F; Ciresi A; Daniele A; Pizzolanti G; Campello E; Frigo AC; Giordano C; Scaroni C
Endocrine; 2018 Oct; 62(1):207-214. PubMed ID: 29980915
[TBL] [Abstract][Full Text] [Related]
12. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.
Manetti L; Bogazzi F; Giovannetti C; Raffaelli V; Genovesi M; Pellegrini G; Ruocco L; Iannelli A; Martino E
Eur J Endocrinol; 2010 Nov; 163(5):783-91. PubMed ID: 20696792
[TBL] [Abstract][Full Text] [Related]
13. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Burman P; Edén-Engström B; Ekman B; Karlsson FA; Schwarcz E; Wahlberg J
Eur J Endocrinol; 2016 Jan; 174(1):17-24. PubMed ID: 26582653
[TBL] [Abstract][Full Text] [Related]
14. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
15. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
16. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.
Castinetti F; Morange I; Jaquet P; Conte-Devolx B; Brue T
Eur J Endocrinol; 2008 Jan; 158(1):91-9. PubMed ID: 18166822
[TBL] [Abstract][Full Text] [Related]
17. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
18. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
19. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
